Sepsis diagnosis and monitoring – procalcitonin as standard, but what next?

Magdalena Mierzchała-Pasierb; Małgorzata Lipińska-Gediga

doi:10.5114/ait.2019.88104

eISSN: 1731-2531
ISSN: 1642-5758

Anaesthesiology Intensive Therapy

Current issue Archive Manuscripts accepted About the journal Supplements Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures

Editorial System

Submit your Manuscript

Open access

Journal integrated with

4/2019
vol. 51

Send email

Copy url:

abstract:

Review article

Sepsis diagnosis and monitoring – procalcitonin as standard, but what next?

Magdalena Mierzchała-Pasierb

¹

,

Małgorzata Lipińska-Gediga

^{2, 3}

Department of Medical Biochemistry, Wroclaw Medical University, Poland

Department of Anesthesiology and Intensive Care, 4th Military Hospital of Wroclaw, Poland

Faculty of Health Science, Wroclaw Medical University, Poland

Anaesthesiol Intensive Ther 2019; 51, 4: 299–305

DOI: https://doi.org/10.5114/ait.2019.88104

Online publish date: 2019/09/25

View full text Get citation

PlumX metrics:

Sepsis is a life-threatening organ dysfunction caused by a systemic altered host response to infection. According to the newest guidelines the sepsis treatment should be personalized and based on an approach specified by use of biomarkers to tailor therapy to each patient’s needs. The main features of such biomarkers should be high specificity, sensitivity and ability to monitor the progress of sepsis. There is limited application of procalcitonin (PCT), C-reactive protein (CRP) and interleukin-6 (IL-6) for reaching this target, because of their secretion during non-infectious processes. The purpose of this review was to introduce four biomarkers, i.e. kallistatin, testican-1, presepsin and mid-regional pro-adrenomedullin, and compare their usefulness in diagnosing sepsis with PCT, CRP and IL-6.

keywords:

Sepsis diagnosis and monitoring – procalcitonin as standard, but what next?

Magdalena Mierzchała-Pasierb 1 , Małgorzata Lipińska-Gediga 2, 3

sepsis, biomarkers, monitoring, mortality

Magdalena Mierzchała-Pasierb

¹

,

Małgorzata Lipińska-Gediga

^{2, 3}